A Phase IIa, Multicentre, Randomised, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate Safety, Tolerability and Clinical Efficacy of MT-1303 in Subjects with Moderate to Severe Chronic Plaque Psoriasis

Trial Profile

A Phase IIa, Multicentre, Randomised, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate Safety, Tolerability and Clinical Efficacy of MT-1303 in Subjects with Moderate to Severe Chronic Plaque Psoriasis

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2015

At a glance

  • Drugs Amiselimod (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 17 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 21 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 21 Nov 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT01987843).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top